Drug resistance related to aberrant glycosylation in colorectal cancer - Université de Lille Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2018

Drug resistance related to aberrant glycosylation in colorectal cancer


Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths in the world. Drug resistance of tumour cells remains the main challenge toward curative treatments efficiency. Several epidemiologic studies link emergence and recurrence of this cancer to metabolic disorders. Glycosylation that modifies more than 80% of human proteins is one of the most widepread nutrient-sensitive post-translational modifications. Aberrant glycosylation participates in the development and progression of cancer. Thus, some of these glycan changes like carbohydrate antigen CA 19-9 (sialyl Lewis a, sLea) or those found on carcinoembryonic antigen (CEA) are already used as clinical biomarkers to detect and monitor CRC. The current review highlights emerging evidences accumulated mainly during the last decade that establish the role played by altered glycosylations in CRC drug resistance mechanisms that induce resistance to apoptosis and activation of signaling pathways, alter drug absorption and metabolism, and led to stemness acquisition. Knowledge in this field of investigation could aid to the development of better therapeutic approaches with new predictive biomarkers and targets tied in with adapted diet.
Fichier principal
Vignette du fichier
22377-316626-7-PB.pdf (5.83 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03167809 , version 1 (12-03-2021)




Ninon Very, Tony Lefebvre, Ikram El Yazidi-Belkoura. Drug resistance related to aberrant glycosylation in colorectal cancer. Oncotarget, 2018, 9 (1), pp.1380-1402. ⟨10.18632/oncotarget.22377⟩. ⟨hal-03167809⟩


19 Consultations
65 Téléchargements



Gmail Mastodon Facebook X LinkedIn More